Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

141. Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Hormone (...) replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than previously thought. Prescribers of HRT should discuss the updated total risk with women using HRT at their next routine appointment. Published 30

Full Text available with Trip Pro

2019 MHRA Drug Safety Update

142. Position Statement – Testing for ovarian cancer in asymptomatic women: Technical Report

Position Statement – Testing for ovarian cancer in asymptomatic women: Technical Report Position Statement – Testing for ovarian cancer on asymptomatic women Technical Report February 2019 Position Statement – Testing for ovarian cancer in asymptomatic women: Technical Report was prepared and produced by: Cancer Australia Locked Bag 3 Strawberry Hills NSW 2012 Australia Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2019. ISBN Online: 978-1-74127-338-0 (...) Recommended citation Cancer Australia, 2019. Position Statement – Testing for ovarian cancer in asymptomatic women: Technical Report, Cancer Australia, Surry Hills, NSW. Position Statement – Testing for ovarian cancer in asymptomatic women: Technical Report can be downloaded from the Cancer Australia website: canceraustralia.gov.au/resources Copyright statements Internet sites This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your

2019 Cancer Australia

143. eUpdate: Bladder Cancer Treatment Recommendations

eUpdate: Bladder Cancer Treatment Recommendations Bladder Cancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO Discover ESMO's new social media (...) , including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer

2019 European Society for Medical Oncology

144. Diagnosis, staging and treatment of patients with oesophageal or oesophagogastric junction cancer

Diagnosis, staging and treatment of patients with oesophageal or oesophagogastric junction cancer National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar Diagnosis, staging and treatment of patients with oesophageal or oesophagogastric junction cancer National Clinical Guideline No. 19 August 2019This National Clinical Guideline has been developed by the National Cancer Control Programme (NCCP) Guideline Development Group, within the Health Service Executive (HSE). Using (...) this National Clinical Guideline This National Clinical Guideline applies to adults (18 years or older) with newly diagnosed oesophageal or oesophagogastric junction (OGJ) cancer, or, those that have a suspected diagnosis of oesophageal or OGJ cancer in a hospital setting. This guideline is intended for all health professionals involved in the diagnosis, staging and treatment of patients with oesophageal or OGJ cancer. While the CEO, General Manager and the Clinical Director of the hospital have corporate

2019 National Clinical Guidelines (Ireland)

145. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer P Pembrolizumab with carboplatin and embrolizumab with carboplatin and paclitax paclitaxel for untreated metastatic el for untreated metastatic squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 11 September 2019 www.nice.org.uk/guidance/ta600 © NICE 2019. All rights reserved. Subject to Notice of rights (https (...) to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

146. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Olaparib for maintenance treatment of Olaparib for maintenance treatment of BR BRCA mutation-positiv CA mutation-positive advanced e advanced o ovarian, fallopian tube or peritoneal varian, fallopian tube or peritoneal cancer after response to first-line cancer after response to first-line platinum-based chemother platinum (...) the environmental impact of implementing NICE recommendations wherever possible. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20Contents Contents 1 Recommendations 4 2 Information about olaparib 5 3 Committee discussion 6 Clinical need

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

147. Antibody-drug conjugates for cancer. (PubMed)

Antibody-drug conjugates for cancer. Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells. To date, five ADCs have received market approval and over 100 are being investigated in various stages of clinical development. In this Therapeutics paper, we review recent clinical experience (...) with the approved ADCs and other promising late-stage candidates on the horizon, following an overview of the biology and chemistry of ADCs and how the individual components of an ADC (antibody [or target], linker and conjugation chemistry, and cytotoxic payload) influence its activity. We briefly discuss opportunities for enhancing ADC efficacy, drug resistance, and future perspectives for this novel antibody-based molecular platform, which has great potential to make a paradigm shift in cancer

2019 Lancet

148. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. (PubMed)

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients (...) with advanced or metastatic disease.Systemic therapy for metastatic non-small cell lung cancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present

2019 JAMA

149. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Pathogenic mutations in breast cancer susceptibility genes BRCA1 and BRCA2 increase risks for breast, ovarian, fallopian tube, and peritoneal cancer in women; interventions reduce risk in mutation carriers.To update the 2013 US Preventive Services Task Force review on benefits and harms of risk assessment, genetic (...) counseling, and genetic testing for BRCA1/2-related cancer in women.Cochrane libraries; MEDLINE, PsycINFO, EMBASE (January 1, 2013, to March 6, 2019, for updates; January 1, 1994, to March 6, 2019, for new key questions and populations); reference lists.Discriminatory accuracy studies, randomized clinical trials (RCTs), and observational studies of women without recently diagnosed BRCA1/2-related cancer.Data on study methods, setting, population characteristics, eligibility criteria, interventions

2019 JAMA

150. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. (PubMed)

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general (...) population, BRCA1/2 mutations occur in an estimated 1 in 300 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.The USPSTF reviewed the evidence on risk assessment, genetic counseling, and genetic testing for potentially harmful BRCA1/2 mutations in asymptomatic women who have never been diagnosed

2019 JAMA

151. Pregnancy duration and endometrial cancer risk: nationwide cohort study. (PubMed)

Pregnancy duration and endometrial cancer risk: nationwide cohort study. To explore the association between pregnancy duration and risk of endometrial cancer.Nationwide register based cohort study.Denmark.All Danish women born from 1935 to 2002.Relative risk (incidence rate ratio) of endometrial cancer by pregnancy number, type, and duration, estimated using log-linear Poisson regression.Among 2 311 332 Danish women with 3 947 650 pregnancies, 6743 women developed endometrial cancer during 57 (...)  347 622 person years of follow-up. After adjustment for age, period, and socioeconomic factors, a first pregnancy was associated with a noticeably reduced risk of endometrial cancer, whether it ended in induced abortion (adjusted relative risk 0.53 (95% confidence interval 0.45 to 0.64) or childbirth (0.66, 0.61 to 0.72). Each subsequent pregnancy was associated with an additional reduction in risk, whether it ended in induced abortion (0.81, 0.77 to 0.86) or childbirth (0.86, 0.84 to 0.89

2019 BMJ

152. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States.To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Preventive Services Task Force.MEDLINE, PubMed, and the Cochrane Collaboration Registry of Controlled Trials, from January 2002 through April 27, 2018 (...) ; surveillance through March 22, 2019.Studies of adults with or without risk factors for pancreatic adenocarcinoma (eg, family history of pancreatic cancer, personal history of new-onset diabetes) undergoing imaging-based screening; studies of treatment for adults with screen-detected or asymptomatic pancreatic adenocarcinoma. Included study designs were randomized clinical trials, nonrandomized controlled intervention studies, diagnostic accuracy studies with a reference standard, cohort studies, and case

2019 JAMA

153. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. (PubMed)

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence (...) of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States.To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer.The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits

2019 JAMA

154. Pancreatic Cancer: Screening

Pancreatic Cancer: Screening Final Recommendation Statement: Pancreatic Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Pancreatic Cancer: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency (...) for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Adults The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients

2019 U.S. Preventive Services Task Force

155. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22) Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC).The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC.This is a French multicenter randomized phase II trial in patients

2019 EvidenceUpdates

156. Hereditary Gastrointestinal Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hereditary Gastrointestinal Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † N. Stjepanovic 1 , L. Moreira 2 , F. Carneiro 3 , F. Balaguer 2 , A. Cervantes 4 , J.Balmaña 1 & E. Martinelli 5 , on behalf of the ESMO Guidelines Committee* 1 Medical Oncology Department, University Hospital Vall d’Hebron, Barcelona, Spain; 2 Gastroenterology Department (...) Institute INCLIVA, University of Valencia, Valencia, Spain; 5 Faculty of Medicine, Università della Campania L Vanvitelli, Naples, Italy. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: May 2019. Running header: ESMO Clinical Practice Guidelines Hereditary gastrointestinal cancers Word count: 5758 (excluding key message, references, tables & figures) Key words

2019 European Society for Medical Oncology

157. ADDENDUM: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

ADDENDUM: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment Michael T. Bashford, MD 1 , Wendy Kohlman, MS 2 , Jessica Everett, MS 3 , Ashley Parrott, MS 4 and Toni I (...) with the following comment: The committees feel that this document remains a useful guide in assessing indications for cancer referral; however, it should not be consideredcomprehensivenorutilizedtolimitaccesstogeneticsprofessionals. Whiletheprinciplesoutlinedforgeneticsreferralforthe specific tumors andsyndromes listedremain valid, inmany casesthe indications forreferral have expanded.The field ofcancer genetics israpidlyevolving,includingfrequentdiscovery ofadditionalgenesandnewclinicalpresentations

2019 American College of Medical Genetics and Genomics

158. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC). The impact of these therapies on survival, and comparability of PD-1 versus PD-L1 blockade are unknown.To determine (...) versus PD-L1 blockade in patients with mUC yields comparable survival outcomes.In this study, we found that outcomes for patients with metastatic bladder cancer treated with programmed death-1 and programmed death ligand-1 inhibitors, who received prior platinum-based chemotherapy, were similar.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 EvidenceUpdates

159. Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer

Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer Colonic J pouch reconstruction has been found to be associated with a lower incidence of anastomotic leakage than straight anastomosis. However, studies on this topic are underpowered and retrospective. This randomized trial evaluated whether the incidence of anastomotic leakage was reduced after colonic J pouch reconstruction compared

2019 EvidenceUpdates

160. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates